The recently IPO'd Foundation Medicine has expanded its relationship with Novartis, lending out its gene-profiling technology to help the drugmaker develop cancer treatments.
Whatever AbbVie learned in the first stages of its collaboration with Seattle Genetics on antibody-drug conjugates must have seriously whetted the pharma company's appetite for more.
Lung cancer spreads quickly, which helps it claim more lives each year than any other cancer worldwide and makes early detection key. Now, two companies have teamed up to bring a diagnostic test to some of the countries that need it most.
Johnson & Johnson's global hunt for new technologies has led it to a fledgling biotech working on a new approach to triggering an immune system attack, as well as stopping one.
Immunocore's list of collaborators is beginning to look like a Who's Who in Big Pharma. Today the biotech--which is developing T cell immunotherapy technology originally spun out of Oxford--added a deal-hungry AstraZeneca and its biologics team at MedImmune as its latest partner, which will now join Genentech and GlaxoSmithKline in exploring whether the biotech has really found a powerful new approach to engineering an immune system attack on cancer cells.
Impax Laboratories is tapping Durect Corporation for its mid-stage transdermal patch Eladur, which is designed to ease the pain associated with shingles. For exclusive rights to the delivery tech, Impax agreed to pay up to $63 million to Durect when all is said and done.
Diagnostics luminary Foundation Medicine has expanded its relationship with pharma giant Novartis, giving the drugmaker more access to its gene profiling technology to develop cancer treatments.
Amid AstraZeneca's deal frenzy to rebuild its weak pipeline, the U.K.-based company has forged another research and licensing deal with Horizon Discovery to find new cancer drug targets.
Stryker announced that it will partner with Samsung unit NeuroLogica to sell a full-body portable computed tomography (CT) scanner. The two companies will market the device for use by surgeons in the fields of neurology, orthopedics and trauma.
The partnership sees Astellas team up with ClearPath, a Maryland-based company that helps develop early-stage drugs.